Resmed opened lower at $246.56, compared with its previous close of $252.83. In the last trading session, the stock traded between $232.36 and $248.05. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Resmed is now worth
$ 88.52
resulting in a loss of
$ 11.48 (11.48%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 11 Analysts
Buy
45.45%
Hold
54.55%
Sell
0%
Markets Today
Today's Change
$-20.11 (-7.95%)
Day High
$248.05
Day Low
$232.36
Day Open
$246.56
Prev Close
$252.83
Volume
15,64,473
1W Return
-8.06%
1M Return
4.40%
3M Return
8.62%
6M Return
9.81%
1Y Return
-8.24%
Fundamentals
Market Cap ($ Mn)
32,730
PE Ratio
23.04
PB Ratio
5.26
PEG Ratio
0.87
ROE
26.11%
ROCE
25.86%
EPS (TTM)
$2.64
Investment Returns
1 Week
-8.06%
1 Month
4.40%
3 Months
8.62%
6 Months
9.81%
9 Months
-9.66%
Financials
Quarterly
All values in $ Mn
1.3K
Mar 25
1.3K
Jun 25
1.3K
Sep 25
1.4K
Dec 25
1.4K
Mar 26
1.5K
Jun 26
Updates
2Oct
Resmed sets Q1FY27 earnings release for October 29, 2026
Resmed releases Q1FY27 results on October 29, 2026. Earnings webcast scheduled for 4:30 pm ET. Phone replay available until November 12, 2026.
ResMed enters $450 million accelerated share repurchase agreement. Citibank acts as counterparty for the transaction. Final share count depends on average trading price. Upfront payment secures immediate and future share delivery.
1mo ago
28Aug
Resmed CEO, CFO to present at Morgan Stanley Healthcare Conference
CEO Mick Farrell and CFO Aaron Bloomer will present at the conference. The event is scheduled for September 15, 2026, in New York. Live audio webcast begins at 10:00 am Eastern Time. Replay available 24 hours post-event for 90 days.
2mo ago
26Aug
Pomerantz investigates ResMed over Q4 miss and safety costs
Pomerantz LLP investigates ResMed for potential securities fraud. Probe follows Q4 FY26 results missing expectations on margins and operating income. Company cited $42 million in field safety costs for Astral respirators. ResMed stock fell 5.06% to $211.94 on August 7, 2026.
2mo ago
25Aug
Resmed partners with NASCAR driver Tyler Reddick on sleep apnea awareness
Resmed partners with NASCAR driver Tyler Reddick to raise awareness of obstructive sleep apnea. Reddick diagnosed with OSA in early 2026; won first three Cup Series races of the season. OSA impacts nearly 1 billion people globally, with over 80% of cases undiagnosed. Resmed branding will appear on Reddick’s car at three select races in late 2026.
2mo ago
18Aug
Resmed appoints Carol Burt as lead director; Ron Taylor to retire
Resmed has named Carol Burt as its new Lead Director, effective November 15, 2026. Burt succeeds Ron Taylor, who is retiring after more than 21 years of service. Taylor will not stand for reelection at the upcoming annual meeting.
